Shots:

• Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close in Q1'22
• The acquisition follows a 2017 collaboration b/w Takeda & GammaDelta to develop GammaDelta's novel d T cell therapy platforms. Takeda will obtain GammaDelta's allogeneic Vd1 gamma-delta (d) T cell therapy platforms including both blood-derived and tissue-derived platforms in addition to early-stage cell therapy programs
• The acquisition will bolster Takeda's immuno-oncology and innate immune cell therapy portfolio with the addition of d T cell therapy platforms for solid tumors & hematological malignancies

 ­to­  | Ref: Takeda | Image: Takeda